AI Article Synopsis
- The study investigates the effectiveness and safety of dobutamine versus milrinone in patients with cardiogenic shock or low cardiac output states.
- Researchers analyzed data from 11 studies involving 21,084 patients, finding that milrinone was linked to lower all-cause mortality, while dobutamine showed a potential for shorter hospital stays.
- Despite these findings, the evidence is limited, and further large-scale randomized trials are needed to clarify the relative benefits and risks of these inotropic agents.
Article Abstract
Objectives: Inotropic support is commonly used in patients with cardiogenic shock (CS). High-quality data guiding the use of dobutamine or milrinone among this patient population is limited. We compared the efficacy and safety of these two inotropes among patients with low cardiac output states (LCOS) or CS.
Data Sources: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were searched up to February 1, 2023, using key terms and index headings related to LCOS or CS and inotropes.
Data Extraction: Two independent reviewers included studies that compared dobutamine to milrinone on all-cause in-hospital mortality, length of ICU stay, length of hospital stay, and significant arrhythmias in hospitalized patients.
Data Synthesis: A total of eleven studies with 21,084 patients were included in the meta-analysis. Only two randomized controlled trials were identified. The primary outcome, all-cause mortality, favored milrinone in observational studies only (odds ratio [OR] 1.19 (95% CI, 1.02-1.39; = 0.02). In-hospital length of stay (LOS) was reduced with dobutamine in observational studies only (mean difference -1.85 d; 95% CI -3.62 to -0.09; = 0.04). There was no difference in the prevalence of significant arrhythmias or in ICU LOS.
Conclusions: Only limited data exists supporting the use of one inotropic agent over another exists. Dobutamine may be associated with a shorter hospital LOS; however, there is also a potential for increased all-cause mortality. Larger randomized studies sufficiently powered to detect a difference in these outcomes are required to confirm these findings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465094 | PMC |
| http://dx.doi.org/10.1097/CCE.0000000000000962 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
VA-ECOM assisted percutaneous mechanical thrombectomy treatment high-risk pulmonary embolism.
Front Cardiovasc Med
December 2024
Department of Vascular Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Background: Percutaneous mechanical thrombectomy (PMT) is increasingly used in the treatment of intermediate and high-risk acute pulmonary embolism (PE), and the treatment of high-risk PE with the aid of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has also been reported. However, there are few reports of VA-ECOM-assisted PMT in the treatment of high-risk PE. The purpose of this study is to summarize the data of 11 patients with high-risk PE treated with VA-ECMO assisted PMT, and propose feasible treatment methods for such patients.
View Article and Find Full Text PDFBiventricular dysfunction predicts mortality in ST elevation myocardial infarction patients with cardiogenic shock.
Egypt Heart J
January 2025
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Jalan Farmako Sekip Utara, Yogyakarta, 55281, Indonesia.
Background: The incidence of mortality in patients with cardiogenic shock due to ST elevation myocardial infarction (STEMI) remains high even with prompt reperfusion therapy. Ventricular systolic dysfunction is the primary condition causing cardiogenic shock in STEMI. Studies have been widely conducted on the left ventricle (LV) and right ventricle (RV) systolic dysfunction related to mortality events.
View Article and Find Full Text PDFNational Cardiogenic Shock Treatment Program in Poland.
Kardiol Pol
January 2024
Institute for Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Inflammatory Heart Disease in Multisystem Inflammatory Syndrome.
Curr Cardiol Rep
January 2025
Robert M. Berne Cardiovascular Research Center, and Department of Medicine, DivisionofCardiovascularMedicine,HeartandVascularCenter, University of Virginia, Charlottesville, VA, USA.
Purposeof The Review: In this review article, we aim to provide an overview of the pathophysiology, the clinical features, the therapeutic management and prognosis of patients affected by Multisystemic inflammatory syndrome (MIS) with cardiac involvement, focusing on myocarditis and pericarditis.
Recent Findings: MIS is a multiorgan hyperinflammatory condition due to a cytokine storm following (within 4-12 weeks) SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) infection. First described in children, it also affects young adults without comorbidities, predominantly males with highly heterogeneous clinical manifestations, including cardiac involvement.
Extracorporeal membrane oxygenation for catecholaminergic polymorphic ventricular tachycardia: a case report and literature review.
BMC Pediatr
January 2025
Department of PICU, Children's Medical Center, the First Hospital of Jilin University, 1 Xinmin Street, Changchun, Jilin Province, China.
Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited ion channelopathy characterized by a structurally normal heart sensitive to catecholamines. It primarily presents as Bidirectional ventricular tachycardia (BiVT) and is a significant cause of sudden cardiac death in children.
Case Presentation: We report our experience with central Extracorporeal Membrane Oxygenation (ECMO) therapy in a 4-year-old boy with CPVT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!